New Clinical Framework Aims to Unify Global Diagnostic Standards for Acute-on-Chronic Liver Failure Treatment

New medical review outlines a unified framework for ACLF, introducing a two-type classification and advanced models to improve survival and global diagnostics.

By: AXL Media

Published: Apr 29, 2026, 7:23 AM EDT

Source: Information for this report was sourced from EurekAlert!

Bridging the Diagnostic Divide Between Eastern and Western Medicine

The medical community is approaching a unified understanding of acute-on-chronic liver failure, a syndrome that has lacked a global diagnostic standard for nearly three decades. A recent review led by Dr. Xiaogang Xiang of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, emphasizes that while regional differences in patient profiles exist, the core clinical features are becoming clearer. Historically, Asian criteria focused on early liver failure driven by hepatitis B, while Western definitions emphasized extrahepatic organ failure. The emergence of a broader consensus is expected to harmonize case identification and improve the reliability of clinical trials across different continents.

Implementing a Two-Tiered Classification System for Early Intervention

In a significant step toward standardization, the Chinese Society of Hepatology proposed a new two-type classification system in 2025. Type I focuses on acute severe liver injury occurring within chronic liver disease without immediate extrahepatic failure, while Type II describes acute decompensation that leads to rapid kidney dysfunction or other organ failures. This structural approach is designed to reconcile the differing priorities of Eastern and Western medical societies. By categorizing patients based on the presence of extrahepatic complications at onset, clinicians can better predict short term mortality and tailor intensive care strategies to the specific progression of the disease.

Uncovering the Biphasic Immune Pathogenesis of Liver Deterioration

Current research reveals that the progression of this condition is often driven by a shared pathway of systemic inflammation, frequently triggered by bacterial infections. The review notes that over 66% of patients suffer from infections, which release inflammatory signals that activate the innate immune system and potentially cause a cytokine storm. Crucially, the study identifies a biphasic immune response where patients first experience excessive immune activation before falling into a state of immune exhaustion or paralysis. This secondary phase significantly elevates the risk of further infections, making the timing of anti-inflammatory and immune modulating treatments a critical factor in patient survival.